arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Corvus Pharmaceuticals, Inc.

CRVS
$12.54 ▼ -0.92 (-6.84%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
47 Visible periods
18 Metrics
Peer-ranked Benchmarks
Price Chart
43
Health
Weak
Bearish
auto_awesome

Analytical Summary

Corvus Pharmaceuticals, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $1.2B
Dividend Yield
Revenue Growth
Op. Margin
ROIC -6.8%
FCF / Share $-0.17
Trailing P/E
Price / Book 4.7x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Sep 23, 2026.

47-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-13.69M
— 0.0%
FCF / Share Free cash flow per share
$-0.17
↓ -128.4%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
25
Cash Quality
87

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 12 years · 47 quarters